ArticleLiver cancer2022

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma.

Masatoshi KudoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.